Selinexor Plus Ruxolitinib Shrinks Spleens but Misses Its Symptom Goal in Phase 3 SENTRY, With an Early Survival Signal in Myelofibrosis
The SENTRY trial of selinexor plus ruxolitinib met its spleen-volume endpoint and missed its symptom endpoint, with an immature overall survival signal favoring the combination.